The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP ... The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed ...

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...

Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...

Associate Professor Qing Zhong shared insights on AI breakthroughs in proteomics and multiomics, challenges in data sharing ...

Repare Therapeutics Inc. (NASDAQ:RPTX – Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 1,130,000 ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%.